Medikinet Cr

Methylphenidate, the active ingredient in Medikinet Cr, is a central nervous system stimulant presented as a tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Medikinet Cr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is used to manage conditions within the central nervous system stimulant therapeutic area.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children, adolescents, and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - Attention deficit disorder (ADD): enhances focus and academic performance in individuals with attention difficulties.

Methylphenidate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Insomnia - Loss of appetite - Headache - Stomach pain - Nausea - Weight loss

Serious or Rare Side Effects: - Cardiovascular events (e.g., hypertension, tachycardia) - Psychiatric symptoms (e.g., psychosis, mania) - Severe allergic reactions (e.g., rash, angioedema) - Growth suppression in children - Tics or worsening of pre‑existing tics

When prescribing Methylphenidate, clinicians should consider several safety precautions.

- Cardiovascular assessment: evaluate heart disease history before initiating therapy. - Psychiatric evaluation: monitor for emergence of psychosis, mania, or severe anxiety. - Growth monitoring: regularly assess height and weight in pediatric patients. - Potential for abuse: assess risk of dependence and misuse. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C, protect from moisture in original packaging.

Methylphenidate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: may reduce blood pressure control. - Antipsychotics: may diminish stimulant effect. - Severe liver impairment drugs: may alter metabolism.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase methylphenidate levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce effectiveness. - Diuretics: may enhance risk of electrolyte imbalance. - Antacids: may affect absorption. - Alcohol: can increase central nervous system side effects.